Difference between revisions of "Ibritumomab tiuxetan (Zevalin)"
m (→References) |
|||
| Line 12: | Line 12: | ||
*[http://chemocare.com/bio/ibritumomab.asp Ibritumomab tiuxetan (Zevalin) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/ibritumomab.asp Ibritumomab tiuxetan (Zevalin) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/ibritumomab.asp Ibritumomab tiuxetan (Zevalin) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/ibritumomab.asp Ibritumomab tiuxetan (Zevalin) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/ibritumomab-patient-drug-information Ibritumomab tiuxetan (Zevalin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ibritumomab-patient-drug-information Ibritumomab tiuxetan (Zevalin) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/ibritumomab-patient-drug-information Ibritumomab tiuxetan (Zevalin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ibritumomab-patient-drug-information Ibritumomab tiuxetan (Zevalin) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *2/19/2002: Granted FDA accelerated approval for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with [[Rituximab (Rituxan)]] refractory follicular non-Hodgkin’s lymphoma. | ||
| + | *9/3/2009: Granted FDA full approval; label expanded for the treatment of previously untreated follicular NHL in patients who achieve a partial or complete response to first-line chemotherapy. | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 17:18, 6 November 2013
General information
Class/mechanism: Anti-CD20 antibody chelated by tiuxetan to a radioactive agent (Y-90, yttrium-90; or In-111, indium-111). Y-90 emits beta radiation, which causes cellular damage via free radicals. This results in damage to cells which express the CD20 antigen (human B-lymphocyte-restricted differentiation antigen, Bp35).[1][2]
Route: IV
Extravasation: potential vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Ibritumomab tiuxetan (Zevalin) patient drug information (Chemocare)[3]
- Ibritumomab tiuxetan (Zevalin) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 2/19/2002: Granted FDA accelerated approval for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan) refractory follicular non-Hodgkin’s lymphoma.
- 9/3/2009: Granted FDA full approval; label expanded for the treatment of previously untreated follicular NHL in patients who achieve a partial or complete response to first-line chemotherapy.